These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

755 related items for PubMed ID: 25670202

  • 21. Deubiquitylase USP9X suppresses tumorigenesis by stabilizing large tumor suppressor kinase 2 (LATS2) in the Hippo pathway.
    Zhu C, Ji X, Zhang H, Zhou Q, Cao X, Tang M, Si Y, Yan H, Li L, Liang T, Feng XH, Zhao B.
    J Biol Chem; 2018 Jan 26; 293(4):1178-1191. PubMed ID: 29183995
    [Abstract] [Full Text] [Related]

  • 22. O-GlcNAcylation on LATS2 disrupts the Hippo pathway by inhibiting its activity.
    Kim E, Kang JG, Kang MJ, Park JH, Kim YJ, Kweon TH, Lee HW, Jho EH, Lee YH, Kim SI, Yi EC, Park HW, Yang WH, Cho JW.
    Proc Natl Acad Sci U S A; 2020 Jun 23; 117(25):14259-14269. PubMed ID: 32513743
    [Abstract] [Full Text] [Related]

  • 23. A kinome-wide screen using a NanoLuc LATS luminescent biosensor identifies ALK as a novel regulator of the Hippo pathway in tumorigenesis and immune evasion.
    Nouri K, Azad T, Lightbody E, Khanal P, Nicol CJ, Yang X.
    FASEB J; 2019 Nov 23; 33(11):12487-12499. PubMed ID: 31431076
    [Abstract] [Full Text] [Related]

  • 24. PAR1 participates in the ability of multidrug resistance and tumorigenesis by controlling Hippo-YAP pathway.
    Fujimoto D, Ueda Y, Hirono Y, Goi T, Yamaguchi A.
    Oncotarget; 2015 Oct 27; 6(33):34788-99. PubMed ID: 26431277
    [Abstract] [Full Text] [Related]

  • 25. STARD13-correlated ceRNA network-directed inhibition on YAP/TAZ activity suppresses stemness of breast cancer via co-regulating Hippo and Rho-GTPase/F-actin signaling.
    Zheng L, Xiang C, Li X, Guo Q, Gao L, Ni H, Xia Y, Xi T.
    J Hematol Oncol; 2018 May 30; 11(1):72. PubMed ID: 29848346
    [Abstract] [Full Text] [Related]

  • 26. Deregulation of the Hippo pathway in mouse mammary stem cells promotes mammary tumorigenesis.
    Li H, Gumbiner BM.
    Mamm Genome; 2016 Dec 30; 27(11-12):556-564. PubMed ID: 27601049
    [Abstract] [Full Text] [Related]

  • 27. KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals.
    Moleirinho S, Chang N, Sims AH, Tilston-Lünel AM, Angus L, Steele A, Boswell V, Barnett SC, Ormandy C, Faratian D, Gunn-Moore FJ, Reynolds PA.
    Oncogene; 2013 Apr 04; 32(14):1821-30. PubMed ID: 22614006
    [Abstract] [Full Text] [Related]

  • 28. The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment.
    Santucci M, Vignudelli T, Ferrari S, Mor M, Scalvini L, Bolognesi ML, Uliassi E, Costi MP.
    J Med Chem; 2015 Jun 25; 58(12):4857-73. PubMed ID: 25719868
    [Abstract] [Full Text] [Related]

  • 29. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
    Shimomura T, Miyamura N, Hata S, Miura R, Hirayama J, Nishina H.
    Biochem Biophys Res Commun; 2014 Jan 17; 443(3):917-23. PubMed ID: 24380865
    [Abstract] [Full Text] [Related]

  • 30. PYK2 negatively regulates the Hippo pathway in TNBC by stabilizing TAZ protein.
    Kedan A, Verma N, Saroha A, Shreberk-Shaked M, Müller AK, Nair NU, Lev S.
    Cell Death Dis; 2018 Sep 24; 9(10):985. PubMed ID: 30250159
    [Abstract] [Full Text] [Related]

  • 31. Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ.
    Kim M, Kim T, Johnson RL, Lim DS.
    Cell Rep; 2015 Apr 14; 11(2):270-82. PubMed ID: 25843714
    [Abstract] [Full Text] [Related]

  • 32. The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell.
    Plouffe SW, Lin KC, Moore JL, Tan FE, Ma S, Ye Z, Qiu Y, Ren B, Guan KL.
    J Biol Chem; 2018 Jul 13; 293(28):11230-11240. PubMed ID: 29802201
    [Abstract] [Full Text] [Related]

  • 33. The Hippo Pathway Prevents YAP/TAZ-Driven Hypertranscription and Controls Neural Progenitor Number.
    Lavado A, Park JY, Paré J, Finkelstein D, Pan H, Xu B, Fan Y, Kumar RP, Neale G, Kwak YD, McKinnon PJ, Johnson RL, Cao X.
    Dev Cell; 2018 Dec 03; 47(5):576-591.e8. PubMed ID: 30523785
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
    Janse van Rensburg HJ, Azad T, Ling M, Hao Y, Snetsinger B, Khanal P, Minassian LM, Graham CH, Rauh MJ, Yang X.
    Cancer Res; 2018 Mar 15; 78(6):1457-1470. PubMed ID: 29339539
    [Abstract] [Full Text] [Related]

  • 36. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway.
    Meng Z, Moroishi T, Mottier-Pavie V, Plouffe SW, Hansen CG, Hong AW, Park HW, Mo JS, Lu W, Lu S, Flores F, Yu FX, Halder G, Guan KL.
    Nat Commun; 2015 Oct 05; 6():8357. PubMed ID: 26437443
    [Abstract] [Full Text] [Related]

  • 37. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
    Hao Y, Chun A, Cheung K, Rashidi B, Yang X.
    J Biol Chem; 2008 Feb 29; 283(9):5496-509. PubMed ID: 18158288
    [Abstract] [Full Text] [Related]

  • 38. Estrogen regulates Hippo signaling via GPER in breast cancer.
    Zhou X, Wang S, Wang Z, Feng X, Liu P, Lv XB, Li F, Yu FX, Sun Y, Yuan H, Zhu H, Xiong Y, Lei QY, Guan KL.
    J Clin Invest; 2015 May 29; 125(5):2123-35. PubMed ID: 25893606
    [Abstract] [Full Text] [Related]

  • 39. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
    Hillen H, Candi A, Vanderhoydonck B, Kowalczyk W, Sansores-Garcia L, Kesikiadou EC, Van Huffel L, Spiessens L, Nijs M, Soons E, Haeck W, Klaassen H, Smets W, Spieser SA, Marchand A, Chaltin P, Ciesielski F, Debaene F, Chen L, Kamal A, Gwaltney SL, Versele M, Halder GA.
    Mol Cancer Ther; 2024 Jan 03; 23(1):3-13. PubMed ID: 37748190
    [Abstract] [Full Text] [Related]

  • 40. TEAD activity is restrained by MYC and stratifies human breast cancer subtypes.
    Elster D, Jaenicke LA, Eilers M, von Eyss B.
    Cell Cycle; 2016 Oct 03; 15(19):2551-2556. PubMed ID: 27433809
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 38.